Celebrating our 10th anniversary – Unlock our special offer today

Free Trial Free TrialFree Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Maryland - United States Bill signed to clarify medical cannabis possession limits ...
  • Louisiana - United States Bill to regulate consumable hemp products heads to Senate ...
  • Maryland - United States Bill signed to increase distance between cannabis dispensaries ...
  • United States Democratic lawmakers urge DEA to ‘promptly’ reschedule cannabis ...
  • Europe Parliament adopts proposal to regulate ecodesign of devices ...
  • Ukraine Plan to use e-prescriptions for medical cannabis open for public discussion ...
  • Europe Packaging and Packaging Waste Directive revision proposal approved ...
  • Europe EU proposal for directive on corporate sustainability due diligence ...
  • Europe European Parliament adopts proposal about right to repair of goods ...
  • Germany BGH sets limit for 'small amount' of cannabis ...
  • United States CPC’s new legislative agenda prioritises cannabis legalisation ...
  • Lithuania Proposed changes to fibre hemp regulation to go to Seimas this week ...
View all
News analysis

Will FDA draw a line between other CBD products and pharmaceuticals?

Written by || 29th April 2019 || News analysis | Health and science | Regulation and legislation | GeographiesNorth America United States

The US FDA is to hold a public hearing on 31st May on the safety of products containing cannabis or cannabis-derived compounds ― and stakeholders will be looking for a dividing line
Read full article

Download the full news analysis

“Will FDA draw a line between other CBD products and pharmaceuticals?”








    I'm already a subscriber

    Login

    Author default picture

    CannIntelligence

    This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

    Our Key Benefits

    The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

    CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

    • Stay informed of any legal and market change in the sector that impacts your organisation
    • Maximise resources by getting market and legal data analysis daily in one place
    • Make smart decisions by understanding how the regulatory and market landscape evolves
    • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

    Thanks for getting in touch with us

    Please leave your enquiry and we will get back to you within 24 hours


      Sign up to our newsletter

      Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis


        See more


        By signing up you agree to our Privacy Policy.